Early effects of intravenous administrations of lansoprazole and famotidine on intragastric pH

Hepato-Gastroenterology

Volumn 56, Issue 90, 2009, Pages 551-554

  Iida, Hiroshi ^a   Inamori, Masahiko ^a   Akimoto, Keiko ^a   Mawatari, Hironori ^a   Endo, Hiroki ^a   Nozaki, Yuichi ^a   Akiyama, Tomoyuki ^a   Ikeda, Tamon ^a   Sakamoto, Yasunari ^a   Fujita, Koji ^a   Yoneda, Kyoko ^a   Takahashi, Hirokazu ^a   Yoneda, Masato ^a   Goto, Ayumu ^a   Abe, Yasunobu ^a   Kobayashi, Noritoshi ^a   Kirikoshi, Hiroyuki ^a   Kubota, Kensuke ^a   Saito, Satoru ^a   Nakajima, Atsushi ^a  

^a YOKOHAMA CITY UNIVERSITY HOSPITAL   (Japan)

Author keywords

Gastric acid; Histamine H 2 receptor; pH monitoring; Proton pump inhibitor

Indexed keywords

CYTOCHROME P450 2C19; DNA; FAMOTIDINE; LANSOPRAZOLE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; GASTRIC PH MONITORING; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STOMACH ACID SECRETION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; CROSS-OVER STUDIES; FAMOTIDINE; GASTRIC ACID; GENOTYPE; HISTAMINE H2 ANTAGONISTS; HUMANS; HYDROGEN-ION CONCENTRATION; INJECTIONS, INTRAVENOUS; MALE; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 67649232747     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Green FW Jr, Kaplan MM, Curtis LE, Levine PH: Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor prolonged gastroduodenal mucosal hemorrhage. Gastroenterology 1978; 74:38-43.
2. Burget DW, Chivertoa SG, Hunt RH: Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 1990; 99:345-51.
3. Kubota T, Chiba K, Ishizaki T: Genotyping of 5- mephenytoun 4'-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 1996; 60: 661-6.
4. de Morais SM, Wilkinson CR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA: The major genetic defect responsible for the polymorphism of S-mephenytoun metabolism in humans. J Biol Chem 1994; 269:15419-22.
5. De Morais SM, Wilkinson CR, Blaisdell J, Meyer UA, Nakainura K, Goldstein JA: Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytom metabolism in Japanese. Mol Pharmacol 1994; 46:594-8.
6. Khoury RM, Katz P0, Castell DO: Post-prandial ranitidine is superior to post-prandial omeprazole in control of gastric acidity in healthy volunteers. Aliment Pharmacol Ther 1999; 13:1211-4.
7. Arnestad JS, Kleveland PM, Waldum HL: In single doses ranitidine effervescent is more effective than lansoprazole in decreasing gastric acidity. Aliment Pharmacol Ther 1997; 11:355-8.
8. Hedenström H, Aim C, Kraft M, Grahnén A; Intragastric pH after oral administration of single doses of ranitidine effervescent tablets, omeprazole capsules and famotidune fast-dissolving tablets to fasting healthy volunteers. Aliment Pharmacol Ther 1997; 11:1137-41.
9. Hurlimann S, Abbühl B, Inauen W, Halter F: Comparison of acid inhihition by either oral high-dose ranitidine or omeprazole. Aliment Pharmacol Ther 1994; 8:193-201.
10. Chassany 0, Bergmann JF, Simoneau C, ElouaerBlanc L, Segrestaa JM, Caulin C: The comparative effects of single intravenous doses of cimetidine, ranitidine, famotidine, and omeprazole on intragastric pH. Curr Ther Res 1996; 57:159-69.
11. Abe Y, Inamori M, Togawa J, Kikuchi T, Muramatsu K, Chiguchi C, Kawamura H, Kobayashi N, Kirikoshi H, Sakaguchi T, Takamura T, Nakajima A, Ueno N, Sekihara H: The comparative effects of single intravenous doses of omeprazole and famotidine on intragastric pH. J Gastroenterol 2004; 39:21-5.
12. Inamori M, Togawa J, Iwasaki T, Ozawa Y, Kikuchi T, Muramatsu K, Chiguchi G, Matsumoto 5, Kawamura H, Abe Y, Kirikoshi H, Kobayashi N, Shimamura T, Kubota K, Sakaguchi T, Saito 5, Ueno N, Nakajima A: Early effects of la.futidine or rabeprazole on intragastric acidity: which drug is more suitable for on-demand use? J Gastroenterol 2005; 40:453-8.
13. Williams MP, Sercombe J, Hamilton MI, Pounder RE: A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 1998; 12:1079-89.
14. Shirai N, Furuta T, Moriyama Y, Okochi H, Kobayashi K, Takashima M, Xiao F, Kosuge K, Nakagawa K, Hanai H, Chiba K, Ohashi K, Ishizaki T: Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 2001; 15:1929-37.
15. Saitoh T, Fukushima Y, Otsuka H, Hirakawa J, Mon H, Asano T, Ishikawa T, Katsube T, Ogawa K, Ohkawa S: Effects rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabobzers. Aument Pharmacol Ther 2002; 16:1811-7.
16. Andersson T: Pharmacokinetics, metabolism and interactions of add pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996; 31:9-28.
17. Funsta T, Ohashi K, Kosuge K, Zhao XJ, Takashima M, Kimura M, Nishimoto M, Hanai H, Kaneko E, Ishizaki T: CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Cliii Pharmacol Ther 1999; 65:552-61.
18. Chremos AN: Pharmacodynamics of famotidine in humans. Am J Med 1986; 81:3-7.
19. Ishizaki T, Horai Y: Cytochrome P450 and the metabolism of proton pump inhibitors: emphasis on rabeprazole (Review Article). Aiiment Pharmacol Ther 1999; 13(Suppl 3):27.36.
20. Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson CR, Branch RA Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 1984; 36:773-80.
21. Nakamura M, Oda M, Akiba Y, Inoue J, Ito T, Tsuchiya M, Ishii H: Autoradiographic demonstration of lansoprazole uptake sites in rat antrum and colon. J Clin Gastroenterol 1995; 20(Suppl 2):S8-13.
22. Moore JG: Stress ulceration in the intensive care unit: use of H2-receptor antagonists. Aliment Pharmacol Ther 1991; 5 Suppl 1:111-9.
23. Cook DJ, Fuller HD, Guyatt GH, Marshall JC, Leasa D, Hall R, Winton TL, Rutledge F, Todd TJ, Roy P: Risk factors for gastrointestinal bleeding in critically dipatients. Canadian Critical Care Trials Group. N Engl J Med 1994; 330:377-81.
24. Shuman RB, Schuster DP, Zuckerman CR: Prophylactic therapy for stress ulcer bleeding: a reapprsosal. Ann Intern Med 1987; 106:562-7.
25. Smythe MA, Zarowitz BJ: Changing perspectives of stress gastritis prophylaxis. Ann Pharmacother 1994; 28:1073-85.
26. Stothert JC Jr, Dellinger EP, Simonowitz DA, Schilling JA: Gastric pH monitoring as a prognostic indicator for the prophylaxis of stress ulceration in the critically III. Am J Surg 1980; 140:761-3.
27. Watanabe Y, Tsumura H, Sasaki H, Morimoto T: The effects of intermittent and continuous intravenous infusion of famotidune on gastric acidity in patients with peptic ulcers. Chin Ther 1990; 12:534-46.
28. Frank WO, Peace ICE, Watson M, Seaman JJ, Szego PL, Braverman A, Mico B, Dickson B: The effect of single intravenous doses of cimetidine or ranitidine on gastric secretion. Chin Pharmacol Ther 1986; 40:665-72.
29. Fullarton GM, Macdonald AM, Mann SC, McColl KE: Controlled study of the effects of intravenous famotidune on intragastric pH in bleeding peptic ulcers. Aliment Pharmacol Ther 1991; 5:77-84.
30. Howden CW, Forrest JA, Reid JL: Effects of single and repeated doses of omeprazole on gastric acid and pepsin secretion in man. Gut 1984; 25:707-10.
31. Jansen JB, Lundborg P, Bank LC, Greve J, Obman M, Stover C, Röhss K, Lasners CB: Effect of single and repeated intravenous doses of omeprazole on pentagastrm stimulated gastric acid secretion and pharmacokinetics m man. Gut 1988; 29:75-80.
32. Cederberg C, Thomson AB, Mahachai V, Westin JA, Kirdeikis P, Fisher U, Zuk L, Marriage B: Effect of intravenous and oral omeprazole on 24-hour intragastric acidity in duodenal ulcer patients. Gastroenterology 1992; 103:913-8.
33. Ohara 5, Hongo M, Asaki 5, Sate A, Shibuya D, Sate H, Motojima T, Yamaguchi N, Ohara T, Tamura T: The effects of famotidine and omeprazole on 24-hour intragastric pH of normal subjects. Nippon Shokakibyo Galckai Zasshi 1988; 85:1353-9.
34. Ducrottfi P, Guillemot F, Elouaer-Blanc L, Hirschauer C, Thorel JM, Petit A, Hochain P, Michel P, Cortot A, Cohn R: Comparison of omeprazole and famotidine on esophageal pH in patients with moderate to severe esophagitis: a cross-over study. Am J Gastroenterol 1994; 89:717-21.
35. Corinaldesi R, DeCiorgio R, Stanghelhini V: Comparison of the antisecretory effects of omeprazole and famotidine on peptone-meal-stimulated gastric acid secretion in patients with duodenal ulcer. Curr Ther Ees 1991; 49:560- 5.